Urinary symptom flare following I-125 prostate brachytherapy

International Journal of Radiation Oncology Biology Physics

Volumn 56, Issue 4, 2003, Pages 1085-1092

  Cesaretti, Jamie A ^a   Stone, Nelson N ^a   Stock, Richard G ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

Brachytherapy; IPSS; Prostate cancer; QOL; Quality of life

Indexed keywords

DOSIMETRY; HORMONES; PATIENT TREATMENT; POPULATION STATISTICS;

URINARY SYMPTOMS;

ONCOLOGY;

HORMONE; IODINE 125; PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; BRACHYTHERAPY; CANCER ADJUVANT THERAPY; CANCER HORMONE THERAPY; CANCER RADIOTHERAPY; CONTROLLED STUDY; DISEASE EXACERBATION; DISEASE SEVERITY; DOSIMETRY; FOLLOW UP; HUMAN; IMPLANTATION; INTERNATIONAL PROSTATE SYMPTOM SCORE; MAJOR CLINICAL STUDY; MALE; MICTURITION; MORBIDITY; PRIORITY JOURNAL; PROSTATE CANCER; RADIATION DOSE; SCORING SYSTEM; STATISTICAL SIGNIFICANCE; SYMPTOMATOLOGY; ULTRASOUND; URINARY DYSFUNCTION;

EID: 0038724750     PISSN: 03603016     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0360-3016(03)00210-4     Document Type: Article

References (40)

1. Bubolz T., Wasson J.H., Lu-Yao G., et al. Treatments for prostate cancer in older men 1984-1997 . Urology. 58:2001;977-982.
2. Mettlin CJ, Murphy GP, Rosenthal DS, et al. The National Cancer Data Base report on prostate carcinoma after the peak in incidence rates in the U.S. The American College of Surgeons Commission on Cancer and the American Cancer Society. Cancer 1988;83:1679-1684.
3. Opportunities in U.S. Prostate Disease Diagnosis and Management Markets - Prostate Cancer Management. Newport Beach, CA: Medical Data International; August 1999.
4. Grimm P.D., Blasko J.C., Sylvester J.E., et al. 10-year biochemical (prostate-specific antigen) control of prostate cancer with I-125 brachytherapy. Int J Radiat Oncol Biol Phys. 51:2001;31-49.
5. Storey M.R., Landgren R.C., Cottone J.L., et al. Transperineal iodine-125 implantation for treatment of clinically localized prostate cancer. 5-year tumor control and morbidity. Int J Radiat Oncol Biol. 43:1999;565-569.
6. Lee W.R., Hall M.C., McQuellon R.P., et al. A prospective quality-of-life study in men with clinically localized prostate carcinoma treated with radical prostatectomy, external beam radiotherapy, or interstitial brachytherapy. Int J Radiat Oncol Biol. 51:2001;614-623.
7. Blasko J.C., Ragda H., Schumacher D. Transperineal ultrasound-guided implantation of the Prostate. Morbidity and complications. Scand J Urol Nephrol. 137:(Suppl):1991;113-118.
8. Kleinberg L., Wallner K., Roy J., et al. Treatment-related symptoms during the first year following transperineal I-125 prostate implantation. Int J Radiat Oncol Biol. 28:1994;985-990.
9. Wallner K., Roy J., Harrison L. Tumor control and morbidity following transperineal iodine 125 implantation for stage T1/T2 prostatic carcinoma. J Clin Oncol. 14:1996;449-453.
10. Desai J., Stock R.G., Stone N.N., et al. Acute urinary morbidity following I-125 interstitial Implantation of the prostate gland. Radiat Oncol Invest. 6:1998;135-141.
11. Gelblum D.Y., Potters L., Ashley R., et al. Urinary morbidity following ultrasound-guided transperineal prostate seed implantation. Int J Radiat Oncol Biol. 45:1999;59-67.
12. Merrick G.S., Butler W.M., Lief J.H., et al. Temporal resolution of urinary morbidity following prostate brachytherapy. Int J Radiat Oncol Biol. 47:2000;121-128.
13. Stock RG, Stone NN, Dalad M. Patient reported long-term urinary morbidity and quality of life following 125-I prostate brachytherapy. J Urol 2000;163:1268 (Abstr.).
14. Brandeis J.M., Litwin M.S., Burnison C.M., et al. Quality of life outcomes after brachytherapy for early stage prostate cancer. J Urol. 163:2000;851-857.
15. Barry M.J., Fowler F.J., O'Leary M.P., et al. The American Urological Association Symptom Index for benign prostatic hyperplasia. J Urol. 148:1992;1549-1557.
16. Cancer staging manual. 1992;Lippincott, Philadelphia.
17. Stock R.G., Stone N.N., Wesson M.F., et al. A modified technique allowing interactive ultrasound guided three dimensional transperineal prostate implantation. Int J Radiat Oncol Biol. 32:1995;219-225.
18. Stock R.G., Stone N.N., Lo Y.C., et al. Postimplant dosimetry for (125)I prostate implants Definitions and factors affecting outcome . Int J Radiat Oncol Biol. 48:2000;899-906.
19. Stock R.G., Stone N.N. Importance of post-implant dosimetry in permanent prostate brachytherapy. Eur Urol. 41:2002;434-439.
20. Mantel N. Evaluations of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep. 50:1966;163-170.
21. Cox DR, Oakes D. Analysis of survival data. London, UK: Chapman and Hall; 1984.
22. Kaplan E.L., Meier P. Non parametric estimation from incomplete observations. J Am Stat Assoc. 53:1958;457-481.
23. Critz F.A., Williams W.H., Benton J.B., et al. Prostate specific antigen bounce after radioactive seed implantation followed by external beam radiation for prostate cancer. J Urol. 163:2000;1085-1089.
24. Barry M.J., Coffey D.C., Fitzpatrick J., et al. Recommendations of the International Consensus Committee concerning patient evaluation for research studies. Cockett A.T.K., Aso Y., Chatelain C. Proceedings of the International Consultation on Benign Prostatic Hypertrophy (BPH). Channel Islands. 1991;279-281 Paris Scientific Communication International, UK.
25. Arterbery V.E., Frazier A., Dalmia P., et al. Quality of life after permanent prostate implant. Semin Surg Oncol. 13:1997;461-464.
26. Desgrandchamps F. Importance of individual response in symptom score evaluation. Eur Urol. 40:(Suppl. 3):2001;2-7.
27. Eckhardt M.D., van Venrooij G.E.P.M., et al. Symptoms and quality of life verses age, prostate volume, and urodynamic parameters in 565 strictly selected men with lower urinary tract symptoms suggestive of benign prostatic hypertrophy. Urology. 57:2001;695-700.
28. Ezz el Din K., Kiemeney L.A., de Wildt M.J., et al. Correlation between uroflowmetry, prostate volume, postvoid residue, and lower urinary tract symptoms as measured by the International Prostate Symptom Score. Urology. 48:1996;393-397.
29. Barry M.J., Cockett A.T.K., Holtgrewe H.L., et al. Relationship of symptoms of prostatism to commonly used physiologic and anatomical measures of the severity of benign prostatic hypertrophy. J Urol. 150:1993;351-358.
30. Yalla S.V., Sullivan M.P., Lecamwasam H.S., et al. Correlation of American Urological Association symptom index with obstructive and nonobstructive prostatism. J Urol. 153:1995;674-679.
31. Boyle P., Gould A.L., Roehrborn C.G. Prostate volume predicts outcome of treatment of benign prostatic hyperplasia with finasteride Meta-analysis of randomized clinical trials . Urology. 48:1996;398-405.
32. Stone N.N., Stock R.G. Permanent seed implantation for localized adenocarcinoma of the prostate. Curr Urol Rep. 3:2002;201-206.
33. Wallner K. Improved outcomes with radiation for prostate cancer. Hematol Oncol Clin North Am. 15:2001;359-375.
34. Potters L., Cao Y., Calugaru E., et al. A comprehensive review of CT-based dosimetry parameters and biochemical control in patients treated with permanent prostate brachytherapy. Int J Radiat Oncol Biol. 50:2001;605-614.
35. Wei J.T., Dunn R.L., Sandler H.M., et al. Comprehensive comparison of health-related quality of life after contemporary therapies for localized prostate cancer. J Clin Oncol. 20:2002;557-566.
36. Penson D.F. Quality of life following prostate cancer treatments. Curr Urol Rep. 1:2000;71-77.
37. Davis J.W., Kuban D.A., Lynch D.F., et al. Quality of life after treatment for localized prostate cancer Differences based on treatment modality . J Urol. 166:2001;947-952.
38. Hanlon A.L., Pinover W.H., Horwitz E.M., et al. Patterns and fate of PSA bounce following 3D-CRT. Int J Radiat Oncol Biol. 50:2001;845-849.
39. Pruthi RS. Re: Prostate specific antigen bounce after radioactive seed implantation followed by external beam radiation for prostate cancer. J Urol 2001;164:2031.
40. Smathers S., Wallner K., Sprouse J., et al. Temporary PSA rises and repeat prostate biopsies after brachytherapy. Int J Radiat Oncol Biol. 50:2001;1207-1211.